UK Viewpoint: AHSNs, AAR And Accelerators – Market Access & Innovation Update
Executive Summary
Dr Charlie Davie, managing director of UCLPartners, a London-based Academic Health Science Partnership and one of the 15 UK Academic Health Science Networks, updates Medtech Insight on key changes in NHS market access policy this summer.
You may also be interested in...
UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word
The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?
Moonshot Projects In Life Sciences Strategy Can Lift UK Over Brexit Hurdle
The long-awaited UK Life Sciences Strategy, part of the industrial strategy proposed after the May government took office in summer 2016, was released today. With input from major medtech organizations and UK-based pharma groups it charts a course ahead for the £64bn national life-sciences industry as the UK seeks to embrace its post-EU future.
Digital Update: UK Peer Pressure, US Tech Advances And EU Common Goals Put eHealth To Top Of Agenda
Funding is taking a long time to come through for the UK NHS's digital health care transformation, but as the national provider's head of technology strategy, Dr Paul Rice says, "We can't afford to remain non-digital." Estonia, currently holding the presidency of the EU Council of Ministers, gets that too, while US digital champions like Kaiser Permanente and disruptive technology inventors like Mindstrong Health are forcing the pace.